(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Exhibit No. | Exhibit | |||||||
99.1 | ||||||||
104 | Cover Page Interactive Data File (embedded within the inline XBRL document). | |||||||
MALLINCKRODT PLC | ||||||||||||||
(registrant) | ||||||||||||||
Date: | November 2, 2021 | By: | /s/ Bryan M. Reasons | |||||||||||
Bryan M. Reasons | ||||||||||||||
Executive Vice President and Chief Financial Officer (principal financial officer) |
MALLINCKRODT PLC | |||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||
(unaudited, in millions, except per share data) | |||||||||||||||||
Three Months Ended | |||||||||||||||||
September 24, 2021 | Percent of Net sales | September 25, 2020 | Percent of Net sales | ||||||||||||||
Net sales | $ | 507.2 | 100.0 | % | $ | 698.3 | 100.0 | % | |||||||||
Cost of sales | 319.2 | 62.9 | 403.0 | 57.7 | |||||||||||||
Gross profit | 188.0 | 37.1 | 295.3 | 42.3 | |||||||||||||
Selling, general and administrative expenses | 127.3 | 25.1 | 220.8 | 31.6 | |||||||||||||
Research and development expenses | 47.3 | 9.3 | 65.5 | 9.4 | |||||||||||||
Restructuring charges, net | 11.0 | 2.2 | 3.2 | 0.5 | |||||||||||||
Gains on divestiture | — | — | (9.7) | (1.4) | |||||||||||||
Opioid-related litigation settlement loss (gain) | 125.0 | 24.6 | (25.8) | (3.7) | |||||||||||||
Medicaid lawsuit | — | — | (0.2) | — | |||||||||||||
Operating (loss) income | (122.6) | (24.2) | 41.5 | 5.9 | |||||||||||||
Interest expense | (48.7) | (9.6) | (62.2) | (8.9) | |||||||||||||
Interest income | — | — | 0.9 | 0.1 | |||||||||||||
Other expense, net | (3.5) | (0.7) | — | — | |||||||||||||
Reorganization items, net | (126.2) | (24.9) | — | — | |||||||||||||
Loss from continuing operations before income taxes | (301.0) | (59.3) | (19.8) | (2.8) | |||||||||||||
Income tax benefit | (32.0) | (6.3) | (211.6) | (30.3) | |||||||||||||
(Loss) income from continuing operations | (269.0) | (53.0) | 191.8 | 27.5 | |||||||||||||
Income (loss) from discontinued operations, net of income taxes | 5.3 | 1.0 | (0.2) | — | |||||||||||||
Net (loss) income | $ | (263.7) | (52.0) | % | $ | 191.6 | 27.4 | % | |||||||||
Basic (loss) income per share: | |||||||||||||||||
(Loss) income from continuing operations | $ | (3.18) | $ | 2.27 | |||||||||||||
Income (loss) from discontinued operations | 0.06 | — | |||||||||||||||
Net (loss) income | $ | (3.11) | $ | 2.26 | |||||||||||||
Diluted (loss) income per share: | |||||||||||||||||
(Loss) income from continuing operations | $ | (3.18) | $ | 2.27 | |||||||||||||
Income (loss) from discontinued operations | 0.06 | — | |||||||||||||||
Net (loss) income | $ | (3.11) | $ | 2.26 | |||||||||||||
Weighted-average number of shares outstanding | |||||||||||||||||
Basic | 84.7 | 84.6 | |||||||||||||||
Diluted | 84.7 | 84.6 |
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
CONSOLIDATED ADJUSTED EBITDA | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||
September 24, 2021 | September 25, 2020 | ||||||||||||||||||||||||||||
Gross Profit | SG&A | R&D | Adjusted EBITDA | Gross Profit | SG&A | R&D | Adjusted EBITDA | ||||||||||||||||||||||
Net loss | $ | 188.0 | $ | 127.3 | $ | 47.3 | $ | (263.7) | $ | 295.3 | $ | 220.8 | $ | 65.5 | $ | 191.6 | |||||||||||||
Adjustments: | |||||||||||||||||||||||||||||
Interest expense, net | — | — | — | 48.7 | — | — | — | 61.3 | |||||||||||||||||||||
Income taxes | — | — | — | (32.0) | — | — | — | (211.6) | |||||||||||||||||||||
Depreciation (1) | 17.3 | (4.3) | (1.6) | 23.2 | 18.3 | (5.5) | (1.7) | 25.5 | |||||||||||||||||||||
Amortization | 144.5 | (0.8) | — | 145.3 | 209.7 | (0.9) | — | 210.6 | |||||||||||||||||||||
Restructuring charges, net | — | — | — | 11.0 | — | — | — | 3.2 | |||||||||||||||||||||
(Income) loss from discontinued operations | — | — | — | (5.3) | — | — | — | 0.2 | |||||||||||||||||||||
Change in contingent consideration fair value | — | 2.1 | — | (2.1) | — | (8.1) | — | 8.1 | |||||||||||||||||||||
Significant legal and environmental charges | — | — | — | 125.0 | 0.7 | (13.4) | — | (11.9) | |||||||||||||||||||||
Gains on divestiture | — | — | — | — | — | — | — | (9.7) | |||||||||||||||||||||
Separation costs | — | (0.1) | — | 0.1 | — | (33.0) | — | 33.0 | |||||||||||||||||||||
Unrealized loss on equity investment | — | — | — | 6.9 | — | — | — | 0.8 | |||||||||||||||||||||
Reorganization items, net | — | — | — | 126.2 | — | — | — | — | |||||||||||||||||||||
Share-based compensation | 0.1 | (1.9) | (0.4) | 2.4 | 0.2 | (3.4) | (0.7) | 4.3 | |||||||||||||||||||||
As adjusted: | $ | 349.9 | $ | 122.3 | $ | 45.3 | $ | 185.7 | $ | 524.2 | $ | 156.5 | $ | 63.1 | $ | 305.4 | |||||||||||||
MALLINCKRODT PLC | |||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||
SEGMENT OPERATING INCOME | |||||||||||
(unaudited, in millions) | |||||||||||
Three Months Ended | |||||||||||
September 24, 2021 | September 25, 2020 | ||||||||||
Specialty Brands | $ | 189.9 | $ | 291.8 | |||||||
Specialty Generics | 15.2 | 43.1 | |||||||||
Segment operating income | 205.1 | 334.9 | |||||||||
Unallocated amounts: | |||||||||||
Corporate and unallocated expenses (1) | (20.8) | (42.1) | |||||||||
Depreciation and amortization | (168.4) | (236.1) | |||||||||
Share-based compensation | (2.4) | (4.3) | |||||||||
Restructuring charges, net | (11.0) | (3.2) | |||||||||
Separation costs | (0.1) | (33.0) | |||||||||
Opioid-related litigation settlement (loss) gain | (125.0) | 25.8 | |||||||||
Medicaid lawsuit | — | (0.5) | |||||||||
Operating (loss) income | $ | (122.6) | $ | 41.5 |
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||
September 24, 2021 | September 25, 2020 | Percent change | Currency impact | Constant-currency growth | |||||||||||||||||||||||||
Specialty Brands | $ | 359.7 | $ | 539.6 | (33.3) | % | 0.1 | % | (33.4) | % | |||||||||||||||||||
Specialty Generics | 147.5 | 159.4 | (7.5) | 0.1 | (7.6) | ||||||||||||||||||||||||
Segment net sales | 507.2 | 699.0 | (27.4) | 0.1 | (27.5) | ||||||||||||||||||||||||
Medicaid lawsuit | — | (0.7) | * | * | * | ||||||||||||||||||||||||
Net sales | $ | 507.2 | $ | 698.3 | (27.4) | % | 0.1 | % | (27.5) | % |
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
SELECT PRODUCT LINE NET SALES AND CONSTANT-CURRENCY GROWTH | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||
September 24, 2021 | September 25, 2020 | Percent change | Currency impact | Constant-currency growth | |||||||||||||||||||||||||
Specialty Brands | |||||||||||||||||||||||||||||
Acthar Gel | $ | 143.4 | $ | 195.3 | (26.6) | % | — | % | (26.6) | % | |||||||||||||||||||
INOmax | 98.4 | 141.9 | (30.7) | — | (30.7) | ||||||||||||||||||||||||
Ofirmev | 4.7 | 88.7 | (94.7) | — | (94.7) | ||||||||||||||||||||||||
Therakos | 62.5 | 62.6 | (0.2) | 0.7 | (0.9) | ||||||||||||||||||||||||
Amitiza | 49.6 | 47.7 | 4.0 | — | 4.0 | ||||||||||||||||||||||||
Other | 1.1 | 3.4 | (67.6) | — | (67.6) | ||||||||||||||||||||||||
Specialty Brands Total | 359.7 | 539.6 | (33.3) | 0.1 | (33.4) | ||||||||||||||||||||||||
Specialty Generics | |||||||||||||||||||||||||||||
Hydrocodone (API) and hydrocodone-containing tablets | 16.9 | 20.0 | (15.5) | — | (15.5) | ||||||||||||||||||||||||
Oxycodone (API) and oxycodone-containing tablets | 15.2 | 16.1 | (5.6) | — | (5.6) | ||||||||||||||||||||||||
Acetaminophen (API) | 49.6 | 54.9 | (9.7) | — | (9.7) | ||||||||||||||||||||||||
Other controlled substances | 60.8 | 62.4 | (2.6) | 0.3 | (2.9) | ||||||||||||||||||||||||
Other | 5.0 | 6.0 | (16.7) | — | (16.7) | ||||||||||||||||||||||||
Specialty Generics Total | 147.5 | 159.4 | (7.5) | 0.1 | (7.6) | ||||||||||||||||||||||||
Segment net sales | 507.2 | 699.0 | (27.4) | 0.1 | (27.5) | ||||||||||||||||||||||||
Medicaid lawsuit | — | (0.7) | * | * | * | ||||||||||||||||||||||||
Net sales | $ | 507.2 | $ | 698.3 | (27.4) | % | 0.1 | % | (27.5) | % | |||||||||||||||||||
MALLINCKRODT PLC | |||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||
(unaudited, in millions, except per share data) | |||||||||||||||||
Nine Months Ended | |||||||||||||||||
September 24, 2021 | Percent of Net sales | September 25, 2020 | Percent of Net sales | ||||||||||||||
Net sales (includes refined estimate of the retrospective one-time charge of $535.1 million related to the Medicaid lawsuit for the nine months ended September 25, 2020) | $ | 1,611.6 | 100.0 | % | $ | 1,530.6 | 100.0 | % | |||||||||
Cost of sales | 958.4 | 59.5 | 1,171.7 | 76.6 | |||||||||||||
Gross profit | 653.2 | 40.5 | 358.9 | 23.4 | |||||||||||||
Selling, general and administrative expenses | 408.3 | 25.3 | 683.2 | 44.6 | |||||||||||||
Research and development expenses | 166.3 | 10.3 | 225.8 | 14.8 | |||||||||||||
Restructuring charges, net | 17.5 | 1.1 | 15.8 | 1.0 | |||||||||||||
Non-restructuring impairment charges | 64.5 | 4.0 | 63.5 | 4.1 | |||||||||||||
Losses (gains) on divestiture | 0.8 | — | (10.1) | (0.7) | |||||||||||||
Opioid-related litigation settlement loss (gain) | 125.0 | 7.8 | (34.1) | (2.2) | |||||||||||||
Medicaid lawsuit | — | — | 105.1 | 6.9 | |||||||||||||
Operating loss | (129.2) | (8.0) | (690.3) | (45.1) | |||||||||||||
Interest expense | (160.7) | (10.0) | (200.9) | (13.1) | |||||||||||||
Interest income | 1.9 | 0.1 | 5.4 | 0.4 | |||||||||||||
Other income, net | 15.9 | 1.0 | 1.1 | 0.1 | |||||||||||||
Reorganization items, net | (329.2) | (20.4) | — | — | |||||||||||||
Loss from continuing operations before income taxes | (601.3) | (37.3) | (884.7) | (57.8) | |||||||||||||
Income tax benefit | (81.9) | (5.1) | (69.2) | (4.5) | |||||||||||||
Loss from continuing operations | (519.4) | (32.2) | (815.5) | (53.3) | |||||||||||||
Income from discontinued operations, net of income taxes | 6.0 | 0.4 | 23.8 | 1.6 | |||||||||||||
Net loss | $ | (513.4) | (31.9) | % | $ | (791.7) | (51.7) | % | |||||||||
Basic loss per share: | |||||||||||||||||
Loss from continuing operations | $ | (6.13) | $ | (9.66) | |||||||||||||
Income from discontinued operations | 0.07 | 0.28 | |||||||||||||||
Net loss | $ | (6.06) | $ | (9.38) | |||||||||||||
Diluted loss per share: | |||||||||||||||||
Loss from continuing operations | $ | (6.13) | $ | (9.66) | |||||||||||||
Income from discontinued operations | 0.07 | 0.28 | |||||||||||||||
Net loss | $ | (6.06) | $ | (9.38) | |||||||||||||
Weighted-average number of shares outstanding: | |||||||||||||||||
Basic | 84.7 | 84.4 | |||||||||||||||
Diluted | 84.7 | 84.4 | |||||||||||||||
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
CONSOLIDATED ADJUSTED EBITDA | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Nine Months Ended | |||||||||||||||||||||||||||||
September 24, 2021 | September 25, 2020 | ||||||||||||||||||||||||||||
Gross Profit | SG&A | R&D | Adjusted EBITDA | Gross Profit | SG&A | R&D | Adjusted EBITDA | ||||||||||||||||||||||
Net loss | $ | 653.2 | $ | 408.3 | $ | 166.3 | $ | (513.4) | $ | 358.9 | $ | 683.2 | $ | 225.8 | $ | (791.7) | |||||||||||||
Adjustments: | |||||||||||||||||||||||||||||
Interest expense, net | — | — | — | 158.8 | — | — | — | 195.5 | |||||||||||||||||||||
Income tax benefit | — | — | — | (81.9) | — | — | — | (69.2) | |||||||||||||||||||||
Depreciation (1) | 52.2 | (13.4) | (4.7) | 70.3 | 54.2 | (16.3) | (5.2) | 75.7 | |||||||||||||||||||||
Amortization | 433.3 | (2.5) | — | 435.8 | 597.2 | (2.6) | — | 599.8 | |||||||||||||||||||||
Restructuring charges, net | — | — | — | 17.5 | — | — | — | 15.8 | |||||||||||||||||||||
Non-restructuring impairment charges | — | — | — | 64.5 | — | — | — | 63.5 | |||||||||||||||||||||
Income from discontinued operations | — | — | — | (6.0) | — | — | — | (23.8) | |||||||||||||||||||||
Change in contingent consideration fair value | — | 7.6 | — | (7.6) | — | (2.4) | — | 2.4 | |||||||||||||||||||||
Significant legal and environmental charges | — | — | — | 125.0 | 535.1 | (53.1) | — | 659.2 | |||||||||||||||||||||
Losses (gains) on divestiture | — | — | — | 0.8 | — | — | — | (10.1) | |||||||||||||||||||||
Separation costs | — | (1.0) | — | 1.0 | — | (75.0) | — | 75.0 | |||||||||||||||||||||
Unrealized gain on equity investment | — | — | — | (4.8) | — | — | — | (2.2) | |||||||||||||||||||||
R&D upfront payment | — | — | — | — | — | — | (5.0) | 5.0 | |||||||||||||||||||||
Reorganization items, net | — | — | — | 329.2 | — | — | — | — | |||||||||||||||||||||
Share-based compensation | 0.4 | (6.6) | (1.4) | 8.4 | 0.8 | (14.0) | (2.8) | 17.6 | |||||||||||||||||||||
As adjusted: | $ | 1,139.1 | $ | 392.4 | $ | 160.2 | $ | 597.6 | $ | 1,546.2 | $ | 519.8 | $ | 212.8 | $ | 812.5 | |||||||||||||
MALLINCKRODT PLC | |||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||
SEGMENT OPERATING INCOME | |||||||||||
(unaudited, in millions) | |||||||||||
Nine Months Ended | |||||||||||
September 24, 2021 | September 25, 2020 | ||||||||||
Specialty Brands | $ | 588.6 | $ | 765.0 | |||||||
Specialty Generics | 73.8 | 155.5 | |||||||||
Segment operating income | 662.4 | 920.5 | |||||||||
Unallocated amounts: | |||||||||||
Corporate and unallocated expenses (1) | (69.1) | (152.3) | |||||||||
Depreciation and amortization | (506.1) | (675.5) | |||||||||
Share-based compensation | (8.4) | (17.6) | |||||||||
Restructuring charges, net | (17.5) | (15.8) | |||||||||
Non-restructuring impairment charges | (64.5) | (63.5) | |||||||||
Separation costs | (1.0) | (75.0) | |||||||||
R&D upfront payment | — | (5.0) | |||||||||
Opioid-related litigation settlement (loss) gain | (125.0) | 34.1 | |||||||||
Medicaid lawsuit | — | (640.2) | |||||||||
Operating loss | $ | (129.2) | $ | (690.3) |
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Nine Months Ended | |||||||||||||||||||||||||||||
September 24, 2021 | September 25, 2020 | Percent change | Currency impact | Constant-currency growth | |||||||||||||||||||||||||
Specialty Brands | $ | 1,149.6 | $ | 1,553.0 | (26.0) | % | 0.3 | % | (26.3) | % | |||||||||||||||||||
Specialty Generics | 462.0 | 512.7 | (9.9) | 0.1 | (10.0) | ||||||||||||||||||||||||
Segment net sales | 1,611.6 | 2,065.7 | (22.0) | 0.2 | (22.2) | ||||||||||||||||||||||||
Medicaid lawsuit | — | (535.1) | * | * | * | ||||||||||||||||||||||||
Net sales | $ | 1,611.6 | $ | 1,530.6 | 5.3 | % | 0.2 | % | 5.1 | % |
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
SELECT PRODUCT LINE NET SALES | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Nine Months Ended | |||||||||||||||||||||||||||||
September 24, 2021 | September 25, 2020 | Percent change | Currency impact | Constant-currency growth | |||||||||||||||||||||||||
Specialty Brands | |||||||||||||||||||||||||||||
Acthar | $ | 423.9 | $ | 576.6 | (26.5) | % | — | % | (26.5) | % | |||||||||||||||||||
Inomax | 338.3 | 438.5 | (22.9) | 0.1 | (23.0) | ||||||||||||||||||||||||
Ofirmev | 24.0 | 216.0 | (88.9) | — | (88.9) | ||||||||||||||||||||||||
Therakos | 197.8 | 174.1 | 13.6 | 2.1 | 11.5 | ||||||||||||||||||||||||
Amitiza | 155.8 | 138.2 | 12.7 | — | 12.7 | ||||||||||||||||||||||||
Other | 9.8 | 9.6 | 2.1 | — | 2.1 | ||||||||||||||||||||||||
Specialty Brands Total | 1,149.6 | 1,553.0 | (26.0) | 0.3 | (26.3) | ||||||||||||||||||||||||
Specialty Generics | |||||||||||||||||||||||||||||
Hydrocodone (API) and hydrocodone-containing tablets | 60.7 | 71.9 | (15.6) | — | (15.6) | ||||||||||||||||||||||||
Oxycodone (API) and oxycodone-containing tablets | 49.5 | 48.0 | 3.1 | — | 3.1 | ||||||||||||||||||||||||
Acetaminophen (API) | 146.8 | 154.5 | (5.0) | — | (5.0) | ||||||||||||||||||||||||
Other controlled substances | 187.9 | 223.8 | (16.0) | 0.3 | (16.3) | ||||||||||||||||||||||||
Other | 17.1 | 14.5 | 17.9 | — | 17.9 | ||||||||||||||||||||||||
Specialty Generics Total | 462.0 | 512.7 | (9.9) | 0.1 | (10.0) | ||||||||||||||||||||||||
Segment net sales | 1,611.6 | 2,065.7 | (22.0) | 0.2 | (22.2) | ||||||||||||||||||||||||
Medicaid lawsuit | — | (535.1) | * | * | * | ||||||||||||||||||||||||
Net sales | $ | 1,611.6 | $ | 1,530.6 | 5.3 | % | 0.2 | % | 5.1 | % |
MALLINCKRODT PLC | |||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||||
(unaudited, in millions) | |||||||||||
September 24, 2021 | December 25, 2020 | ||||||||||
Assets | |||||||||||
Current Assets: | |||||||||||
Cash and cash equivalents | $ | 1,322.6 | $ | 1,070.6 | |||||||
Accounts receivable, net | 431.7 | 538.8 | |||||||||
Inventories | 367.6 | 344.9 | |||||||||
Prepaid expenses and other current assets | 203.7 | 350.0 | |||||||||
Total current assets | 2,325.6 | 2,304.3 | |||||||||
Property, plant and equipment, net | 767.7 | 833.1 | |||||||||
Intangible assets, net | 5,684.1 | 6,184.5 | |||||||||
Other assets | 380.6 | 393.5 | |||||||||
Total Assets | $ | 9,158.0 | $ | 9,715.4 | |||||||
Liabilities and Shareholders' Equity | |||||||||||
Current Liabilities: | |||||||||||
Current maturities of long-term debt | $ | 1,388.1 | $ | 3,587.9 | |||||||
Accounts payable | 122.2 | 93.3 | |||||||||
Accrued payroll and payroll-related costs | 62.7 | 79.4 | |||||||||
Accrued interest | 25.7 | 26.9 | |||||||||
Accrued and other current liabilities | 387.1 | 331.2 | |||||||||
Total current liabilities | 1,985.8 | 4,118.7 | |||||||||
Pension and postretirement benefits | 32.6 | 34.6 | |||||||||
Environmental liabilities | 60.3 | 59.8 | |||||||||
Deferred income taxes | 61.5 | 80.6 | |||||||||
Other income tax liabilities | 82.9 | 100.1 | |||||||||
Other liabilities | 86.0 | 109.8 | |||||||||
Liabilities subject to compromise | 6,335.5 | 4,192.6 | |||||||||
Total Liabilities | 8,644.6 | 8,696.2 | |||||||||
Shareholders' Equity: | |||||||||||
Preferred shares | — | — | |||||||||
Ordinary shares | 18.9 | 18.8 | |||||||||
Ordinary shares held in treasury at cost | (1,616.1) | (1,616.1) | |||||||||
Additional paid-in capital | 5,596.0 | 5,587.6 | |||||||||
Retained deficit | (3,474.9) | (2,961.5) | |||||||||
Accumulated other comprehensive loss | (10.5) | (9.6) | |||||||||
Total Shareholders' Equity | 513.4 | 1,019.2 | |||||||||
Total Liabilities and Shareholders' Equity | $ | 9,158.0 | $ | 9,715.4 |
MALLINCKRODT PLC | |||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||
(unaudited, in millions) | |||||||||||
Nine Months Ended | |||||||||||
September 24, 2021 | September 25, 2020 | ||||||||||
Cash Flows From Operating Activities: | |||||||||||
Net loss | $ | (513.4) | $ | (791.7) | |||||||
Adjustments to reconcile net cash from operating activities: | |||||||||||
Depreciation and amortization | 506.1 | 675.5 | |||||||||
Share-based compensation | 8.4 | 17.6 | |||||||||
Deferred income taxes | (19.1) | 304.0 | |||||||||
Non-cash impairment charges | 64.5 | 63.5 | |||||||||
Losses (gains) on divestiture | 0.8 | (10.1) | |||||||||
Reorganization items, net | 22.5 | — | |||||||||
Other non-cash items | (6.0) | (21.6) | |||||||||
Changes in assets and liabilities: | |||||||||||
Accounts receivable, net | 105.7 | 61.1 | |||||||||
Inventories | (30.9) | (43.9) | |||||||||
Accounts payable | 14.7 | (52.4) | |||||||||
Income taxes | 92.5 | (431.2) | |||||||||
Opioid-related litigation settlement liability | 125.0 | — | |||||||||
Medicaid lawsuit | (4.8) | 640.2 | |||||||||
Other | 40.4 | (116.3) | |||||||||
Net cash from operating activities | 406.4 | 294.7 | |||||||||
Cash Flows From Investing Activities: | |||||||||||
Capital expenditures | (39.2) | (42.4) | |||||||||
Proceeds from divestitures, net of cash | 15.7 | (0.7) | |||||||||
Other | 1.4 | 6.7 | |||||||||
Net cash from investing activities | (22.1) | (36.4) | |||||||||
Cash Flows From Financing Activities: | |||||||||||
Repayment of external debt | (128.2) | (134.6) | |||||||||
Debt financing costs | — | (9.3) | |||||||||
Repurchase of shares | — | (0.4) | |||||||||
Other | — | (36.3) | |||||||||
Net cash from financing activities | (128.2) | (180.6) | |||||||||
Effect of currency rate changes on cash | (0.9) | 0.2 | |||||||||
Net change in cash, cash equivalents and restricted cash | 255.2 | 77.9 | |||||||||
Cash, cash equivalents and restricted cash at beginning of period | 1,127.0 | 822.6 | |||||||||
Cash, cash equivalents and restricted cash at end of period | $ | 1,382.2 | $ | 900.5 | |||||||
Cash and cash equivalents at end of period | $ | 1,322.6 | $ | 844.2 | |||||||
Restricted cash included in prepaid expenses and other assets at end of period | 23.3 | 20.2 | |||||||||
Restricted cash included in other long-term assets at end of period | 36.3 | 36.1 | |||||||||
Cash, cash equivalents and restricted cash at end of period | $ | 1,382.2 | $ | 900.5 |